Am ixture of (Z)-2-(2,4-dichlorobenzylidene)-6,7-dihydro-2H-thiazolo[3,2-a]pyrimidin-3(5H)-one (1 mmol) and nitrile oxide (1 mmol) were refluxed in dioxane (60 ml) until the disappearence of the starting material as evidenced by the TLC. After the reaction was over, the solvent was removed in vacuo and the residue was separated by column chromatography (silica gel, petroleum ether/ethylacetate =5 :1) to give the title compound. 20 . mg of the product was dissolved in 15 ml dichloromethanehexane mixed solvent. The solution was kept at room temperature for 15 dbynatural evaporation to give colorless single crystals suitable for X-ray analysis.
Discussion
The molecule contains an 4,5-dihydro-1,2,4-oxadiazole ring, a thiazolidine ring, and an hexahydropyrimidine ring. The thiazolidine ring (C1/N1/C2/ C3/S1) has envelope conformation. C1/N1/ C2/C3 are nearly on plane with the mean deviation from this plane of 0.0180(3) Å.T he S1 lies 0.2854(3) Å below the C1/N1/C2/C3 plane of thiazolidine ring, forms the flap of the envelope. The 4,5-dihydro-1,2,4-oxadiazole ring (C1/N2/C14/ N3/O2) is nearly planar with the mean deviation of 0.0141(3) Å. The dihedral angle between the C1/N2/C14/N3/O2 plane and the phenyl plane (C15/C16/C17/C18/C19/C20) is 92.0(4)°.T he hexahydropyrimidine ring has the twist conformation. 
